To the full analysis
Phibro Animal Health stock: valuation and P/E
PAHCPhibro Animal Health trades at a P/E of 14.1 (Drug Manufacturers (Specialty & Generic) median 18.9, own median of recent years 21.6).
Daily figure as of 13 Nov 2026
P/E
14.1
P/S
0.9
P/B
3.48
PEG
1.47
Against its own valuation history
Each fiscal year is shown with its P/E on the year-end date, using the price at the time.
P/E
14.1
Median of prior years
21.6
Reading
cheaper than usual
P/E at each fiscal year end
Figures as a table
| Year | P/E |
|---|---|
| 2017 | 22.7 |
| 2018 | 28.6 |
| 2019 | 23.4 |
| 2020 | 31.7 |
| 2021 | 21.6 |
| 2022 | 15.8 |
| 2023 | 16.9 |
| 2024 | 284 |
| 2025 | 21.5 |
| 2026 | 12.8 |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 30 Jun 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 6 Mar 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.